New York-Presbyterian Hospital-Columbia

Massachusetts General Hospital

Supported by: AstraZeneca
This promotional program covers the HIMALAYA trial of the IMFINZI + IMJUDO immunotherapy regimen in patients with unresectable HCC. The presentation has been updated with results from the HIMALAYA 4-year exploratory analysis sho

Supported by: An Exelixis Product for the Clinical Management of HCC  
Presenter:
Julio A. Gutierrez, MD, MS

Supported by: Mallinckrodt Pharmaceuticals
Presenter:
Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG

Supported by:  Labcorp
NIS4® is a blood-based test designed to effectively identify patients with at-risk metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). The more recently developed NIS2+™ is an optimized version of NIS4® that was

Supported by: Intercept Pharmaceuticals, Inc.
Join us for an informative presentation that discusses taking treatment for Primary Biliary Cholangitis (PBC) a step further. Learn about an approved therapy for patients with PBC.
Presenters:
Kris Kowdley,

Supported by: Alnylam Pharmaceuticals
AHP is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks of which the cardinal symptom is severe, diffuse abdominal pain. This presentation will provide a disease overview an

Supported by:  Ipsen 
In primary biliary cholangitis, it is important to look beyond the liver to make meaningful improvements for patients, so how can we optimize regular disease monitoring alongside the impact of symptoms on patients’ lives? Join us to